Results from Cardiovascular Outcome Trials in Diabetes
Endocrinol Nutr. 2016 Aug-Sep;63(7):317-9.
doi: 10.1016/j.endonu.2016.04.001.
Epub 2016 Jun 17.
[Article in
English,
Spanish]
Affiliations
- 1 UGC Endocrinología y Nutrición, Hospital Universitario San Cecilio, Complejo Hospitalario Universitario de Granada, Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, España. Electronic address: mmt@mamuto.es.
- 2 UGC Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, España.
No abstract available
MeSH terms
-
Benzhydryl Compounds / therapeutic use
-
Cardiovascular Diseases / epidemiology
-
Cardiovascular Diseases / etiology
-
Cardiovascular Diseases / prevention & control*
-
Clinical Trials as Topic*
-
Diabetes Complications / drug therapy*
-
Diabetes Mellitus, Type 2 / drug therapy
-
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
-
Glucagon-Like Peptide-1 Receptor / antagonists & inhibitors
-
Glucosides / therapeutic use
-
Hospitalization
-
Humans
-
Hypoglycemic Agents / pharmacology
-
Hypoglycemic Agents / therapeutic use*
-
Molecular Targeted Therapy
-
Sodium-Glucose Transporter 2
-
Sodium-Glucose Transporter 2 Inhibitors
-
Treatment Outcome
Substances
-
Benzhydryl Compounds
-
Dipeptidyl-Peptidase IV Inhibitors
-
Glucagon-Like Peptide-1 Receptor
-
Glucosides
-
Hypoglycemic Agents
-
SLC5A2 protein, human
-
Sodium-Glucose Transporter 2
-
Sodium-Glucose Transporter 2 Inhibitors
-
empagliflozin